We have studied the interaction of the Gal-GalNAc-reactive champedak lectin-C with neuraminidase-treated and untreated IgA1 from IgA nephropathy patients. The binding ability of the lectin to untreated IgA1 from IgA nephropathy patients was significantly lower as compared to the untreated IgA1 from normal controls. This differential lectin-binding capacity was abrogated when the experiment was performed on neuraminidase-treated sera. Treatment of the serum IgA1 with neuraminidase also abrogated the differential charge distribution between the α-heavy chains of IgA nephropathy patients and normal controls.
© 2001 S. Karger AG, Basel
Dr. O.H. Hashim
Department of Biochemistry
Faculty of Medicine, University of Malaya
Kuala Lumpur 50603 (Malaysia)
Received: Accepted: December 15, 2000
Number of Print Pages : 4
Number of Figures : 3, Number of Tables : 0, Number of References : 12
Founded 1964 by G. Richet and G.E. Schreiner
Vol. 89, No. 4, Year 2001 (Cover Date: December 2001)
Journal Editor: G.M. Berlyne, Brooklyn, N.Y./Beersheva; S. Ito, Sendai
ISSN: 0028–2766 (print), 1423–0186 (Online)
For additional information: http://www.karger.com/journals/nef
Article / Publication Details
Published online: 11/22/2001
Issue release date: 2001
Number of Print Pages: 4
Number of Figures: 3
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: http://www.karger.com/NEF
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.